Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T20:01:47.655Z Has data issue: false hasContentIssue false

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

Published online by Cambridge University Press:  02 January 2018

S. Blomhoff*
Affiliation:
Department of Psychosomatic and Behavioural Medicine, National Hospital, Oslo, Norway
T. T. Haug
Affiliation:
Department of Psychiatry, Haukeland University Hospital, Bergen, Norway
K. Hellström
Affiliation:
Department of Neuroscience and Psychiatry, Ulleraaker University Hospital, Uppsala, Sweden
I. Holme
Affiliation:
Life Insurance Companies Institute for Medical Statistics, Ullevaal University Hospital, Oslo, Norway
M. Humble
Affiliation:
Department of Psychiatry, Huddinge University Hospital, Huddinge, Sweden
H. P. Madsbu
Affiliation:
Elverum Medical Center, Elverum, Norway
J. E. Wold
Affiliation:
Department of Child and Adolescent Psychiatry, Innherred Hospital, Levanger, Norway
*
Svein Blomhoff, Department of Psychosomatic and Behavioural Medicine, National Hospital, N-0027 Oslo, Norway
Rights & Permissions [Opens in a new window]

Abstract

Background

No controlled trial of treatment of generalised social phobia has been conducted in general practice.

Aims

To examine the efficacy of sertraline or exposure therapy, administered alone or in combination in this setting.

Method

Study was of a randomised, double-blind design. Patients (n=387) received sertraline 50–150 mg or placebo for 24 weeks. Patients were additionally randomised to exposure therapy or general medical care.

Results

Sertraline-treated patients were significantly more improved than non-sertraline-treated patients (χ2=12.53, P<0.001; odds ratio=0.534; 95% CI 0.347–0.835). No significant difference was observed between exposure— and non-exposure-treated patients (χ2=2.18, P=0.140; odds ratio=0.732; 95% CI 0.475–1.134). In the pairwise comparisons, combined sertraline and exposure (χ2=12.32; P<0.001) and sertraline (χ2=10.13; P=0.002) were significantly superior to placebo.

Conclusions

Sertraline is an effective treatment for generalised social phobia. Combined treatment with sertraline and exposure therapy, conducted by the general practitioner, may enhance the treatment efficacy in primary care.

Information

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2001 
Figure 0

Fig. 1Trial profile.

Figure 1

Table 1Outcome after 24 weeks of treatment (n=354)

Figure 2

Fig. 2Number of participants approaching response during treatment. * denotes P<0.05 compared with placebo. Weeks 12, 16: sertraline plus exposure therapy; Week 24: sertraline plus exposure therapy, sertraline. Response criteria: reduction of at least 50% on Social Phobia Scale; Clinical Global Impression — Social Phobia (CGI—SP) scale overall severity score ‘no mental illness’ to ‘mild severity’ (<3); and CGI—SP overall improvement score very much or much improved (<2).

Figure 3

Fig. 3Number of participants improved (responders or partial responders) during treatment. * denotes P<0.05 compared with placebo. Week 8: sertraline plus exposure therapy; Week 12: sertraline plus exposure therapy, sertraline, exposure therapy; Weeks 16, 24: sertraline plus exposure therapy, sertraline. Improvement criteria: all responses better than non-response (defined as less than 25% reduction on Social Phobia Scale, or Clinical Global Impression — Social Phobia overall improvement rating of no change or worse).

Figure 4

Table 2Primary efficacy variables: changes in Clinical Global Impression — Social Phobia (CGI—SP) severity sub-scale and Social Phobia Scale (SPS) during treatment and CGI—SP improvement sub-scale at final examination

Figure 5

Table 3Secondary efficacy variables: changes in Brief Social Phobia Scale (BSPS), Fear of Negative Evaluations (FNE), Fear Questionnaire (FQ), Sheehan Disability Inventory (SDI), and the mental sub-scale of Short-Form—36 (SF—36) during treatment

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.